Veterinary medicine and science · 2026
Gastroscopic Evaluation of Gastric Mucosa in Horses Treated With Flunixin Meglumine or High-Dose Firocoxib: A Descriptive Pilot Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
de Oliveira Renato Abrantes, Correa Alexandre da Silva, Monteiro Francisco Décio de Oliveira, Teixeira Pedro Paulo Maia
Аннотация
BACKGROUND: Equine Gastric Ulcer Syndrome (EGUS) is common in horses, and nonsteroidal anti-inflammatory drugs (NSAIDs) are a known risk factor for gastrointestinal ulceration. Although COX-2 selective NSAIDs such as firocoxib theoretically offer a better safety profile, endoscopic evidence for their mucosal safety at high off-label doses is lacking.
OBJECTIVES: To compare the effects of label-dose flunixin meglumine and high-dose firocoxib on the gastric mucosa of a small selected group of horses using serial gastroscopy and histopathology in a descriptive pilot study.
METHODS: Twenty mixed-breed horses were allocated non-randomly to control (n = 10), flunixin meglumine (1.1 mg/kg IM, n = 5), or firocoxib (1.0 mg/kg PO, n = 5) groups, treated once daily for 5 days. Gastroscopic evaluation and histopathological analysis were performed before (Day 1) and after treatment (Day 6).
RESULTS: No glandular disease was observed. Low prevalence of pre-existing squamous lesions was found in all groups without progression after treatment. Histopathological scores revealed baseline incomparability, with marked cellular infiltrate present only in the flunixin group at Day 1 (60%). Within-group analyses showed no significant changes between time points (p > 0.05). The use of NSAIDs effectively resolved lameness.
CONCLUSIONS: In this small descriptive pilot study, limited by non-randomised allocation and small sample size, the study found no detectable short-term gastric mucosal injury associated with high-dose firocoxib within the limits of this study. Due to the non-randomised design, no causal conclusions can be drawn. These hypothesis-generating findings require confirmation in adequately powered randomised trials.
OBJECTIVES: To compare the effects of label-dose flunixin meglumine and high-dose firocoxib on the gastric mucosa of a small selected group of horses using serial gastroscopy and histopathology in a descriptive pilot study.
METHODS: Twenty mixed-breed horses were allocated non-randomly to control (n = 10), flunixin meglumine (1.1 mg/kg IM, n = 5), or firocoxib (1.0 mg/kg PO, n = 5) groups, treated once daily for 5 days. Gastroscopic evaluation and histopathological analysis were performed before (Day 1) and after treatment (Day 6).
RESULTS: No glandular disease was observed. Low prevalence of pre-existing squamous lesions was found in all groups without progression after treatment. Histopathological scores revealed baseline incomparability, with marked cellular infiltrate present only in the flunixin group at Day 1 (60%). Within-group analyses showed no significant changes between time points (p > 0.05). The use of NSAIDs effectively resolved lameness.
CONCLUSIONS: In this small descriptive pilot study, limited by non-randomised allocation and small sample size, the study found no detectable short-term gastric mucosal injury associated with high-dose firocoxib within the limits of this study. Due to the non-randomised design, no causal conclusions can be drawn. These hypothesis-generating findings require confirmation in adequately powered randomised trials.